S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
OTCMKTSMKTS:EROX

Human Pheromone Sciences Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume324 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta2.6
Human Pheromone Sciences, Inc. engages in the research, development, manufacture, and marketing of consumer products containing synthetic human pheromones and other mood enhancing compounds in the United States and internationally. It provides a line of fragrance and toiletry products for men and women under the Natural Attraction trademark. The company also licenses its initial compounds and related technology, as well as sells its patented compounds to licensed customers to include these compounds as components in their products. In addition, it offers private label manufacturing services to licensed customers. Human Pheromone Sciences, Inc. distributes its products through distributors, as well as through the Web site, naturalattraction.com. The company was formerly known as EROX Corporation and changed its name to Human Pheromone Sciences, Inc. in May 1998. Human Pheromone Sciences, Inc. was founded in 1989 and is headquartered in San Jose, California.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange OTCMKTSMKTS
Industry Toilet preparations
Sub-IndustryN/A
Current SymbolOTCMKTSMKTS:EROX
CUSIPN/A
CIKN/A
Phone408-938-3030
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive EROX News and Ratings via Email

Sign-up to receive the latest news and ratings for EROX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Human Pheromone Sciences (OTCMKTSMKTS:EROX) Frequently Asked Questions

What stocks does MarketBeat like better than Human Pheromone Sciences?

Wall Street analysts have given Human Pheromone Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Human Pheromone Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Human Pheromone Sciences' key executives?

Human Pheromone Sciences' management team includes the following people:
  • Mr. William P. Horgan, Chairman, CEO & Pres (Age 73)
  • Mr. Gregory S. Fredrick, CFO, Principal Accounting Officer, VP - Fin. and Assistant Sec. (Age 66, Pay $106.3k)
  • Mr. Julian N. Stern, Sec.

Who are some of Human Pheromone Sciences' key competitors?

What is Human Pheromone Sciences' stock symbol?

Human Pheromone Sciences trades on the OTCMKTSMKTS under the ticker symbol "EROX."

How do I buy shares of Human Pheromone Sciences?

Shares of EROX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Human Pheromone Sciences' official website?

The official website for Human Pheromone Sciences is www.naturalattraction.com.

How can I contact Human Pheromone Sciences?

The company can be reached via phone at 408-938-3030.


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.